Most biotech teams track competitors with a spreadsheet someone updates when they remember to. That works until a rival posts topline data at ASCO and your VP of Commercial finds out from a Slack link. We build a standing intelligence system that watches ClinicalTrials.gov, conference abstracts, payer coverage decisions, and KOL sentiment, and turns it into decisions your team can act on before the news cycle does.
The Problem
Pipeline changes get discovered by accident
A competitor updates a trial's primary endpoint or pushes a readout date on ClinicalTrials.gov, and your team finds out three weeks later from an analyst note. By then the board has already asked why nobody flagged it. Trial registry changes are public and timestamped, but nobody owns watching them full-time.
Conference disclosures land with no prep window
ASCO, JPM Healthcare Conference, and ASH abstracts publish on fixed release schedules that everyone in the industry knows about, yet most companies scramble the same week the embargo lifts. Sales and medical affairs get blindsided in front of physicians who already read the abstract. A reactive scramble in week one costs you the narrative for the whole quarter.
Payer and PBM moves outrun commercial planning
A competing therapy gets favorable formulary placement or a step-therapy requirement shifts, and your market access team hears about it from a frustrated field rep instead of a monitoring system. Payer coverage decisions move faster than annual planning cycles account for, and they directly change what your reps can say and what patients can access.
KOL sentiment shifts before anyone notices
Key opinion leaders start hedging on your mechanism in a panel discussion or a podcast appearance, and it takes months to show up in prescribing data. By the time the trend is visible in sales numbers, the sentiment shift already happened and you spent that window unaware. Waiting for lagging indicators means you're always negotiating from behind.
How We Help
We start with an audit of what you're already tracking and what's slipping through. Most biotech teams have fragments: someone follows a few competitors on LinkedIn, someone else gets a Google Alert digest, and nobody owns the whole picture. We map your top 5-8 direct competitors by mechanism and indication, then build the monitoring infrastructure to watch them continuously instead of episodically.
The core of the system is trial registry tracking. We monitor ClinicalTrials.gov for status changes, enrollment updates, endpoint modifications, and estimated completion date shifts across every competitor asset in your therapeutic area. This is public data that most companies simply aren't watching in a structured way. We turn raw registry noise into a short list of changes that actually matter to your program.
Next we build a conference disclosure calendar tied to ASCO, JPM Healthcare Conference, ASH, and the other 2-3 conferences relevant to your indication. Abstract release dates, embargo lifts, and late-breaker slots get mapped weeks in advance so your medical affairs and commercial teams walk into conference season with a briefing instead of a surprise.
On the commercial side, we track payer and PBM coverage decisions for competing therapies, including formulary tier placement, prior authorization criteria, and step-therapy requirements. We also monitor competitor launch messaging, sales collateral, and how their reps are positioning against you in the field, so your commercial team knows what story they're up against before a rep hears it from a physician.
KOL sentiment tracking rounds out the system. We watch what the physicians who influence your category are saying in panels, podcasts, published commentary, and conference Q&A, looking for directional shifts before they show up in prescribing trends. This isn't social listening software pointed at hashtags. It's a small set of specific, high-signal voices tracked deliberately.
Every piece feeds into one output: a monitoring cadence with a threshold for what gets escalated immediately versus what shows up in the regular briefing. Most competitive intel efforts fail because everything is treated as urgent, so nothing is. We build the filter first.
We measure this by whether decisions get made faster and with less surprise. Did your team have a point of view ready before a competitor's data dropped, or after? Did commercial planning adjust before the payer decision took effect, or scramble afterward? That's the standard we hold the system to.
What we deliver
- Competitor pipeline tracker: standing monitor of ClinicalTrials.gov status, endpoints, and timeline changes for your top competitive assets, updated on a defined cadence
- Conference disclosure calendar: mapped abstract release dates and embargo windows for ASCO, JPM Healthcare Conference, ASH, and indication-specific conferences, with pre-briefs before each
- Payer and commercial intelligence brief: recurring summary of formulary decisions, PA/step-therapy changes, and competitor launch messaging affecting your market access position
- KOL sentiment log: tracked commentary from the physicians who move opinion in your category, flagged for directional shifts before they hit prescribing data
By the time a pipeline change shows up in an analyst note, it's been public on ClinicalTrials.gov for weeks. The teams that win aren't smarter. They're just watching sooner.
Our Methodology
We run this as a 90-day sprint before it becomes a standing operating rhythm. The first 30 days are spent mapping your competitive set, auditing every existing source of intel you have (however informal), and standing up the pipeline and conference tracking infrastructure. You get your first real briefing by week four, not a slide about what a briefing will eventually look like.
Days 31-60 add the payer and commercial layer, plus the KOL sentiment log. This is where the system starts producing intelligence your commercial and medical affairs teams actually use in weekly planning, not just something the strategy team reads and files away. We adjust the escalation thresholds based on what your team says is noise versus what's genuinely actionable.
By day 90 the system runs on its own cadence, and we hand you a clear model for who owns what internally if you want to bring it in-house, or we stay on as the standing monitoring function. Either way, you leave the sprint with infrastructure, not a one-time report that goes stale the week after we deliver it.
How We Work
Weeks 1-4 (foundation): we audit current intel sources, define your competitive set with your clinical and commercial leads, and stand up ClinicalTrials.gov and conference disclosure tracking. First briefing ships by the end of this phase.
Weeks 5-8 (expansion): we layer in payer/PBM monitoring and KOL sentiment tracking, and start running a regular briefing cadence, typically weekly with an immediate-escalation path for material changes.
Weeks 9-12 (operationalize): we tune thresholds based on what your team actually acts on, document the system, and set the ongoing structure, whether that's WF running it standing or your team taking it over with our infrastructure.
You work directly with a small team, typically a lead strategist and a research analyst, not a rotating account team. Expect a standing weekly touchpoint plus async updates when something material happens between meetings. Monthly engagement fees for this kind of standing intelligence function typically run $8,000 to $20,000 depending on how many competitors and how many conferences you're tracking.
- Faster internal response time to competitor pipeline and conference disclosures, measured by how far ahead of the news your team had a point of view
- Commercial and market access planning that adjusts to payer decisions before they take effect instead of after
- A defensible, documented intelligence trail your board and investors can see, instead of ad hoc updates pulled together under deadline
If your biotech & pharma company needs competitive intelligence leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does biotech competitive intelligence work cost?
Standing monitoring engagements typically run $8,000 to $20,000 per month, scaled to how many competitors and conferences you're tracking. A narrower engagement covering just pipeline and conference tracking for 3-4 direct competitors sits at the lower end. Adding payer/PBM monitoring and KOL sentiment tracking across a broader competitive set moves you toward the higher end.
How long until we see a usable output?
You get your first real competitive briefing within the first 30 days, built from the pipeline and conference tracking we stand up immediately. The full system, including payer monitoring and KOL sentiment tracking, is fully operational by day 90. We don't wait until the end of the engagement to show you something useful.
Do we need to hire someone internally to manage this?
No. We can run this as a standing function with no internal hire required, or build the system and hand off ownership to an internal analyst if you'd rather bring it in-house at the end of the 90-day sprint. Most Series A to growth-stage biotech companies don't have headcount for a dedicated competitive intelligence role, which is exactly the gap this fills.
How is this different from hiring a market research agency?
Traditional market research agencies deliver a report and move on to the next client. We build standing infrastructure that runs continuously and gets tuned based on what your team actually uses, not what looks good in a deck. We also work inside your commercial and medical affairs planning cycles directly, so the intelligence shows up where decisions get made instead of sitting in an inbox.
How do you measure ROI on competitive intelligence?
We track it through response time and decision quality: how far ahead of a competitor's public disclosure did your team have a point of view, and did commercial planning shift before a payer decision took effect or scramble after. These aren't vanity metrics. They're the difference between your board asking why you didn't know and you telling them what you're already doing about it.
What kind of biotech or pharma company is the right fit for this?
Series A through growth-stage companies with at least one clinical-stage asset and a competitive landscape worth tracking are the best fit, typically $5 million to $100 million in ARR or an equivalent pre-revenue clinical-stage company preparing for a major readout or launch. If you have zero direct competitors or you're pre-IND, this isn't the right engagement yet.
